A surprise positive opinion from regulators in Europe regarding Encysive Pharmaceuticals Inc.'s Thelin took the sting out of the less happy news from U.S. regulators earlier this year, and Wall Street rewarded the company with a stock boost of about 35 percent. (BioWorld Today) Read More
